PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research

Recently, immunotherapy has become the fourth pillar of cancer treatment in addition to surgery therapy, chemotherapy, and radiation therapy. The inhibitors of programed cell death protein 1 (PD-1) and its ligand PD-L1 are the new stars in immunotherapy, as they can overcome tumor immunosuppression....

Full description

Bibliographic Details
Main Authors: Yu Zhang, Guang-Ze Mou, Tian-Zhu Li, Wan-Ting Xu, Tong Zhang, Hui Xue, Wen-Bo Zuo, Yan-Nan Li, Ying-Hua Luo, Cheng-Hao Jin
Format: Article
Language:English
Published: SAGE Publishing 2021-03-01
Series:Technology in Cancer Research & Treatment
Online Access:https://doi.org/10.1177/15330338211004942
Description
Summary:Recently, immunotherapy has become the fourth pillar of cancer treatment in addition to surgery therapy, chemotherapy, and radiation therapy. The inhibitors of programed cell death protein 1 (PD-1) and its ligand PD-L1 are the new stars in immunotherapy, as they can overcome tumor immunosuppression. However, the efficacy of PD-1 inhibitors still needs to be further developed for clinical treatment. Therefore, research into treatment with anti-PD-1 drugs has emerged as a new development field. This review provides novel insights into the role and mechanism of PD-1 combination anti-tumor therapy, thereby promoting its clinical application in anti-tumor immunotherapy.
ISSN:1533-0338